JP2023541432A5 - - Google Patents
Info
- Publication number
- JP2023541432A5 JP2023541432A5 JP2023516476A JP2023516476A JP2023541432A5 JP 2023541432 A5 JP2023541432 A5 JP 2023541432A5 JP 2023516476 A JP2023516476 A JP 2023516476A JP 2023516476 A JP2023516476 A JP 2023516476A JP 2023541432 A5 JP2023541432 A5 JP 2023541432A5
- Authority
- JP
- Japan
- Prior art keywords
- medication
- administration
- days
- composition according
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078844P | 2020-09-15 | 2020-09-15 | |
| US63/078,844 | 2020-09-15 | ||
| PCT/JP2021/033855 WO2022059692A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541432A JP2023541432A (ja) | 2023-10-02 |
| JP2023541432A5 true JP2023541432A5 (https=) | 2024-08-14 |
| JP7828333B2 JP7828333B2 (ja) | 2026-03-11 |
Family
ID=80776678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516476A Active JP7828333B2 (ja) | 2020-09-15 | 2021-09-15 | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230390251A1 (https=) |
| EP (1) | EP4213842B1 (https=) |
| JP (1) | JP7828333B2 (https=) |
| KR (1) | KR20230067647A (https=) |
| AU (1) | AU2021345171A1 (https=) |
| TW (1) | TW202227060A (https=) |
| WO (1) | WO2022059692A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011121453A2 (en) * | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| US10889555B2 (en) | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| MA51228A (fr) | 2017-11-29 | 2020-10-07 | Taiho Pharmaceutical Co Ltd | Agent antitumoral |
-
2021
- 2021-09-15 JP JP2023516476A patent/JP7828333B2/ja active Active
- 2021-09-15 KR KR1020237012413A patent/KR20230067647A/ko active Pending
- 2021-09-15 AU AU2021345171A patent/AU2021345171A1/en active Pending
- 2021-09-15 TW TW110134368A patent/TW202227060A/zh unknown
- 2021-09-15 EP EP21869378.6A patent/EP4213842B1/en active Active
- 2021-09-15 WO PCT/JP2021/033855 patent/WO2022059692A1/en not_active Ceased
- 2021-09-15 US US18/026,515 patent/US20230390251A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541432A5 (https=) | ||
| JP2023541430A5 (https=) | ||
| JP2023501627A5 (https=) | ||
| JP2022180461A5 (https=) | ||
| JP2023041862A5 (https=) | ||
| JP2021066744A5 (ja) | ブプロピオンおよびデキストロメトルファンを含む組成物 | |
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| JP2023519965A5 (https=) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2011173928A5 (https=) | ||
| JP2020509024A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| AR070842A1 (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2019515909A5 (https=) | ||
| JP2018531273A5 (https=) | ||
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| JP2018138596A5 (https=) | ||
| JP2022551691A5 (https=) | ||
| JP2025148449A5 (https=) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2008517991A5 (https=) | ||
| JP2006503095A5 (https=) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2022550828A5 (https=) |